Vulvovaginal Candidiasis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for vulvovaginal candidiasis. 5 active patents protecting 1 drugs from 1+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
5
Active US patents
42/100
Avg vulnerability
—
Annual revenue covered

Originators in Vulvovaginal Candidiasis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

GSK 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating vulvovaginal candidiasis. Each bar = one year. Y-axis scaled to peak year (3 patents).

1
30
3
35
1
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Brexafemme
IBREXAFUNGERP CITRATE
 GSK 5 42 — 2030-08-28

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11534433 Brexafemme method of use 70 2039-06-10
8188085 Brexafemme method of use 68 2030-08-28
10370406 Brexafemme method of use 62 2035-01-19
10174074 Brexafemme composition of matter 4 2035-01-19
10927142 Brexafemme composition of matter 4 2035-01-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10174074 Brexafemme composition of matter 4 2035-01-19
10927142 Brexafemme composition of matter 4 2035-01-19
10370406 Brexafemme method of use 62 2035-01-19
8188085 Brexafemme method of use 68 2030-08-28
11534433 Brexafemme method of use 70 2039-06-10

Related